News
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
Ben Katz, chief executive officer of Happy Head, holds three degrees from the University of Pennsylvania, including an M.B.A.
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
9h
The Print on MSNMounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trialBoth medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...
A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...
WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...
14h
Study Finds on MSNWeight Loss Showdown: Mounjaro (Tirzepatide) Trounces Wegovy in Head-to-Head TrialIn a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results